• Valion Bio disclosed a U.S. government-funded AFRRI/NIAID program testing Entolimod for lethal radiation-induced gastrointestinal injury.
• Results have not been presented; top-line therapeutic data are expected in early fall.
• A safety study is set to start this week to confirm tolerability in AFRRI’s mouse strain.
• A follow-on therapeutic study will test post-exposure dosing to support survival and gastrointestinal recovery in a model designed to isolate GI benefit.
• A positive readout could broaden Entolimod’s positioning as a radiation countermeasure beyond blood-system protection, strengthening its strategic value for preparedness programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608120929ACCESSWRNAPR_____1206414) on August 12, 2026, and is solely responsible for the information contained therein.